In our aging society, with an increased urgency to develop new compounds that target serious illnesses like Alzheimer’s and Parkinson’s disease, memory enhancement drugs are becoming a big business. But these same drugs are also creating a growing ethical controversy over their potential off-label uses, such as taking these drugs as “performance enhancers” to gain a competitive advantage in the workplace.
Get the full story...
Preemies between 28 and 32 weeks are not harmed by a treatment no longer used to help their lungs mature before birth, according to findings of a study in this month's Pediatrics. Even though previous observational studies suggested that repeated courses of steroids in the womb may result in brain damage, this study shows that the babies' brains are virtually unaffected.
Read the full story
